« FT Chimes In on State of Pharma Industry | Main | Amgen Pushes Ahead With Son of Dmab »



TrackBack URL for this entry:

Listed below are links to weblogs that reference Should FDA Hit The Brakes On Accelerated Approval? :


Feed You can follow this conversation by subscribing to the comment feed for this post.


The harm to an individual dying patient I imagine is certainly mitigated by their severe disease circumstances - but even for such a patient it is not hard to imagine circumstances where a drug might speed death or cause additional side effects. But the real harm I think occurs with the next patient and the patient after that if you have a therapy repeatedly being administered that doesn't work. In that sense, it also harms the science and knowledge base if you can't or aren't measuring that effect.


If the patient is dying with no other treatment available....what's the harm? None to the patient. Then to whom? Hmmmmm, let me guess.

The comments to this entry are closed.

My Photo
Blog powered by Typepad
Member since 12/2009
Bookmark and Share

July 2014

Sun Mon Tue Wed Thu Fri Sat
    1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31    

Innovate on Purpose

In the Pipeline

Life Sci VC

visited 6 states (46.1%)
Create your own visited map of Canada